Singapore markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
17.75+0.19 (+1.08%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close17.56
Open17.49
Bid17.67 x 900
Ask17.74 x 1300
Day's range17.49 - 18.03
52-week range9.25 - 25.46
Volume215,669
Avg. volume604,531
Market cap1.106B
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
EPS (TTM)-2.41
Earnings date10 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.00
  • Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
    Business Wire

    Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021

    Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

  • Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
    Business Wire

    Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration

    Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). The absence of a specific HSCT-TMA diagnosis code has led to underreporting of diagnoses and inaccurate coding, which has complicated reporting of the incidence and outcomes of the disease. This new ICD-10 code, which will be effective October 1, 2021, will for the first time allow clinicians, payers and others to accurately track the incidence of HSCT-TMA. Additional instructions about how to report the code will be available from the CDC later this year.

  • Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
    Business Wire

    Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial

    Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative. The goal of the trial is to screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.